Omnicare acquires excelleRx for $269M

Omnicare has agreed to buy excelleRx for $269 million in a move aimed at absorbing the company's technology and call center for pharmaceutical services. Philadelphia-based excelleRx provides pharmaceutical products and care services for hospices.

- read this press release for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.